Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2008-10-27
2010-06-29
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reexamination Certificate
active
07744875
ABSTRACT:
The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
REFERENCES:
patent: 5811097 (1998-09-01), Allison et al.
patent: 5855887 (1999-01-01), Allison et al.
patent: 6051227 (2000-04-01), Allison et al.
patent: 6682736 (2004-01-01), Hanson et al.
patent: 6984720 (2006-01-01), Korman et al.
patent: 7452535 (2008-11-01), Davis et al.
patent: 7465446 (2008-12-01), Lowy et al.
patent: 2002/0039581 (2002-04-01), Carreno et al.
patent: 2002/0086014 (2002-07-01), Korman et al.
patent: 2004/0241169 (2004-12-01), Lowy et al.
patent: 2007/0160619 (2007-07-01), Nichol et al.
patent: WO 00/37504 (2000-06-01), None
patent: WO 01/14424 (2001-03-01), None
patent: WO 03/086459 (2003-10-01), None
patent: WO 2005/003298 (2005-01-01), None
Beck et al., J. Clin. Oncol., 2006, 24: 2283-2289.
Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0, DCTD, NCI, NIH, DHHS, Mar. 31, 2003.
Chambers, Cynthia A., et al., “Lymphoproliferation in CTLA-4-Deficient Mice is Mediated by Costimulation-Dependent Activiation of CD4+T Cells,” Immunity, Dec. 1997, vol. 7, pp. 885-895.
Chambers, Cynthia A., et al., “Co-stimulation in T cell responses,” Curr. Opin. Immunol., 1997, vol. 9, pp. 396-404.
Damle, Nitin K., et al., “Alloantigen-Specific Cytotoxic and Suppressor T Lymphocytes are Derived from Phenotypically Distinct Precursors,” The Journal of Immunology, Nov. 1983, vol. 131, No. 5, pp. 2296-2300.
Hurwitz, Arthur A., et al., “CTLA-R blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma,” Proc. Natl. Acad. Sci., Aug. 1998, pp. 10067-10071.
Hurwitz, Arthur A., et al., “Immunotherapy of Primary Prostate Cancer in a Transgenic Model Using a Combination of CTLA-4 Blockade and Tumor Cell Vaccine,” Cancer Research, May 1, 2000, vol. 60, pp. 2444-2448.
International Search Report for PCT/US2004/016995, mailed May 10, 2005.
Janik et al., “A Pilot Study of MDX-010 After Vaccine Failure In Patients With Advanced Malignacy,” Blood, vol. 102, No. 11, p. 647A, Nov. 16, 2003.
Kearney, Elizabeth R., et al., “Antigen-Dependent Clonal Expansion of a Trace Population of Antigen-Specific CD4+ T Cells in Vivo is Dependent on CD28 Costimulation and Inhibited by CTLA-41,” The Journal of Immunology, 1995, vol. 155, pp. 1032-1036.
Leach, Dana R., et al., “Enhancement of Antitumor Immunity by CTLA-4 Blockade,” Science, Mar. 22, 1996, vol. 271, pp. 1734-1736.
Lindsten, Tullia, et al., “Regulation of Lymphokine Messenger RNA Stability by Surface-Mediated T Cell Activation Pathway,” Science, Apr. 21, 1989, vol. 224, pp. 339-343.
Luhder, Fred, et al., “Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes,” J. Exp. Med., Feb. 2, 1998, vol. 187, No. 3, pp. 427-432.
Matsui, Toshihiro, et al., “Autoantibodies to T-Cell Costimulatory Molecules in Systemic Autoimmune Diseases,” The Journal of Immunology, 1999, vol. 162, pp. 4328-4335.
Overwijk, Willem M., et al., “Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CDR+ T lymphocytes,” Proc. Natl. Acad. Sci., Mar. 1999, vol. 96, pp. 2982-2987.
Perrin, Peter J., et al., “CTLA-4 Blockade Enhances Clinical Disease and Cytokine Production During Experimental Allergic Encephalomyelitis 1, 2” The Journal of Immunology, vol. 157, pp. 1333-1336.
Phan et al., “Cancer Regression and Autoimmunity Induced by Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients With Metastatic Melanoma,” Proceedings of The National Academy of Sciences of USA, vol. 100, No. 14, pp. 8372-8377, Jul. 8, 2003.
Rosenberg, Steven A., et al., “Vitiligo in Patients with Melanoma: Normal Tissue Antigens Can Be Targets for Cancer Immunotherapy,” Journal of Immunotherapy, vol. 19, No. 1, pp. 81-84.
Thompson, Craig B., et al., “CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines,” Proc. Natl. Acad. Sci., Feb. 1989, vol. 86, pp. 1333-1337.
Van Elsas, Andrea, et al., “Combination Immunotherapy of B16 Melanoma Using Anti-Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA-4) and Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF)-producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation,” J. Exp. Med., Aug. 2, 199, vol. 190, No. 3, pp. 355-366.
Van Elsas, et al., “Elucidating the autoimmune and antitumor effector mechanism of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy,” J. Exp. Med. 20 Aug. 2001, V. 194, pp. 481-489, especially abstract, p. 482.
Walunas, Theresa L., et al., “CTLA-4 Can Function as a Negative Regulator of T Cell Activation,” Immunity, Aug. 1994, vol. 1, pp. 405-413.
Ansell et al., “Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-hodgkin lymphoma,”Clin. Cancer Res.(2009);15(20):6446-6453.
Attia, et al. “Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.”J Clin Oncol. (2005);23(25):6043-53.
Bashey et al., “CTLA-4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation,”Blood(2009);113:1581-1588.
Bashey et al., “Phase I study of a neutralizing monoclonal anti-CTLA-4 antibody (MDX-010) in patients with relapse of malignancy after allogeneic hematopoietic stem cell transplantation,”Biology of Blood and Marrow Transplantation(2005);11(2):5.
Balzano, et al.“CTLA-4 and CD28: similar proteins, neighbouring genes.”Int J Cancer Suppl. (1992);7:28-32.
Camacho et al., “Phase I/II Trial of Tremelimumab in patients with metastatic melanoma,”J. Clin. Oncol. (2009);27:1075-1081.
Camacho et al., “Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies,”J. Clin. Oncol.(2004) ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol. 22, No. 14S (Jul. 15 Suppl.), 2004:2505.
Céspedes MV, et al., “Mouse models in oncogenesis and cancer therapy,”Clin Transl Oncol. (2006);8(5):318-29.
Dennis C, “Cancer: off by a whisker,”Nature. (2006);442(7104):739-41.
Downey SG, et al., “Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade,”Clin Cancer Res. (2007);13(22 Pt 1):6681-8.
Gulley JL and Dahut WL, “Future directions in tumor immunotherapy: CTLA4 blockade,”Nat Clin Pract Oncol. (2007);4(3):136-7.
Gura T, “Systems for identifying new drugs are often faulty,”Science. (1997);278(5340):1041-2.
Hodi et al., “Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients,”PNAS(2008);105(8):3005-3010.
Jain, “Barriers to Drug Delivery in Solid Tumors,”Scientific AmericanJul. 1994, 58-65.
Bluestone, “Is CTLA-4 a master switch for peripheral T cell tolerance?”J Immune. (1997);158(5):1989-93.
Krummel and Allison, “CD28 and CTLA-4 Have Opposing Effects on the Response of T cells to Stimulation.”J.Exp.Med. (1995);182:459-465.
Krummel, et al. “Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo”International Immunology(1996);8(4):519-523.
Langer LF, et al., ȁ
Lowy Israel
Nichol Geoffrey M.
Baker & Botts L.L.P.
Medarex Inc.
Ouspenski Ilia
LandOfFree
Surrogate therapeutic endpoint for anti-CTLA-4 based... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Surrogate therapeutic endpoint for anti-CTLA-4 based..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Surrogate therapeutic endpoint for anti-CTLA-4 based... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4250996